药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Veltuzumab
The risk or severity of adverse effects can be increased when Veltuzumab is combined with Brentuximab vedotin.
Mecasermin
Farletuzumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Brentuximab vedotin.
Mecasermin
Ramucirumab
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Brentuximab vedotin.
Mecasermin
Enokizumab
The risk or severity of adverse effects can be increased when Enokizumab is combined with Brentuximab vedotin.
Mecasermin
Iratumumab
The risk or severity of adverse effects can be increased when Iratumumab is combined with Brentuximab vedotin.
Mecasermin
AMG 108
The risk or severity of adverse effects can be increased when AMG 108 is combined with Brentuximab vedotin.
Mecasermin
Otelixizumab
The risk or severity of adverse effects can be increased when Otelixizumab is combined with Brentuximab vedotin.
Mecasermin
NAV 1800
The risk or severity of adverse effects can be increased when NAV 1800 is combined with Brentuximab vedotin.
Mecasermin
XTL-001
The risk or severity of adverse effects can be increased when XTL-001 is combined with Brentuximab vedotin.
Mecasermin
Obiltoxaximab
The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Brentuximab vedotin.
Mecasermin
Girentuximab
The risk or severity of adverse effects can be increased when Girentuximab is combined with Brentuximab vedotin.
Mecasermin
Rozrolimupab
The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Brentuximab vedotin.
Mecasermin
CR002
The risk or severity of adverse effects can be increased when CR002 is combined with Brentuximab vedotin.
Mecasermin
Bavituximab
The risk or severity of adverse effects can be increased when Bavituximab is combined with Brentuximab vedotin.
Mecasermin
Fontolizumab
The risk or severity of adverse effects can be increased when Fontolizumab is combined with Brentuximab vedotin.
Mecasermin
Matuzumab
The risk or severity of adverse effects can be increased when Matuzumab is combined with Brentuximab vedotin.
Mecasermin
Labetuzumab
The risk or severity of adverse effects can be increased when Labetuzumab is combined with Brentuximab vedotin.
Mecasermin
Adecatumumab
The risk or severity of adverse effects can be increased when Adecatumumab is combined with Brentuximab vedotin.
Mecasermin
IGN311
The risk or severity of adverse effects can be increased when IGN311 is combined with Brentuximab vedotin.
Mecasermin
Oregovomab
The risk or severity of adverse effects can be increased when Oregovomab is combined with Brentuximab vedotin.